REGNRegeneron PharmaceuticalsRunning, no new patients
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Melanoma
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 1,564 (final count)
- Started
- Jan 16, 2023
- Main results expected
- Jul 27, 2026
- Fully finished
- Apr 3, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Relapse free survival (RSF)
Measured over: Up to 5 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05608291 · record last updated 2026-07-06 · checked 2026-11-09 15:47 UTC